Final Report

Final Report - Bioengineering 10-Final Paper Executive...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
e 2: The St. Jude Medical mechanical heart valve. [11] 3: CryoValve SynerGraft Pulmonary Heart Valve. [5] igure 5: Freedom from Explant (ROSS). [5] gure 6: Freedom from Explant. (RVOT) [5] Bioengineering 10--Final Paper Executive Summary Valvular heart disease is one of the leading causes of death in the United States. Although the “cure” for the disease has been established for a relatively long time, there are still some significant problems that must be tackled. While many pharmaceuticals are being developed to tackle valvular heart disease, some degrees of valvular heart disease cannot be cured with the use of medications. In the case that the patient’s disease is not treatable with medications, the patient must undergo a valve replacement. While the design of pharmaceuticals is a rapidly growing and necessary field in biomedical sciences, it is nothing without the development of replacement valves. With such an increasing number of individuals developing imperfect heart valves, it is crucial that the advancements in replacements valves maintain development. CryoLife has contributed significantly to this field with their range of replacement heart valves, such as the CryoValve SG. Since many other companies manufacture near identical devices, CryoLife made their device stand out from the others by utilizing a breakthrough process called SynerGraft that increases the durability and lifetime of the heart valve. The CryoValve SG creates a foundation for the next generation of biological tissues. Compared to other heart valves, the CryoValve is the first heart valve to reduce allogeneic donor cells and cell remnants associated with standard processing techniques. In turn, the valve is able to maintain the structural integrity of the biological matrix vital to long-term durability and function of the valve. The CryoValve SG utilizes the breakthrough process called SynerGraft. SynerGraft processing successfully reduces allogeneic cells and cell remnants. The SynerGraft- processed valves retain structural integrity, and at the same time are able retain hydrodynamic functionality. Many breakthroughs have been made in the cardiovascular field, but when CryoLife introduced the CryoValve SG, one large step was taken toward the “prefect cure” for valvular heart disease. By examining this unique heart valve, including the advantages, disadvantages, clinical trials, and even mechanism of action, we can gain a thorough outline of the promise the CryoValve SG presents to the field of medicine. Clinical Problem The term valvular heart disease refers to any abnormality or dysfunction of one or more of the heart’s four valves. The four valves include the mitral valve and the aortic valve on the left side, and the tricuspid valve and pulmonic valve on the right side. Each of the four valves in your heart has a set of flaps (or leaflets) and when each of them works properly, the heart valves open and close fully. Not only can an individual be born with
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 09/24/2009 for the course BIOENGR 10 taught by Professor Staff during the Spring '08 term at UCLA.

Page1 / 12

Final Report - Bioengineering 10-Final Paper Executive...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online